Sourasky Medical Center (Ichilov)
| イスラエル | トルコ | オーストリア | |
| 血漿交換術 | から $2,200 | から $1,200 | から $2,000 |
| 臍帯血幹細胞療法 | から $14,500 | から $5,000 | から $7,500 |
| 選択的アフェレーシス | - | から $1,550 | - |
| 血漿交換 | - | から $3,900 | - |
| 治療的アフェレーシス | - | から $1,350 | - |
Bookimedは免疫学治療価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。国に到着時にクリニックで治療代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。免疫学治療で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。免疫学治療の旅路でお一人になることはありません。
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Dr. Einat Shacham‑Shmueli is a senior medical oncologist at the Gastrointestinal Clinic, Cancer Center, Sheba Medical Center. She treats cancers of the colon, stomach, and pancreas. She also manages metastatic disease. She uses precision diagnostics and biomarkers, systemic therapies, and radiotherapy. Care is provided within a multidisciplinary team.
She has authored more than 25 peer‑reviewed papers on GI oncology, tumor biology, and new treatments. Her work includes studies on stenting for malignant colonic obstruction. She serves as an investigator in international programs, including the NCI, the Radiation Therapy Oncology Group, and the Cancer Therapy Evaluation Program.
Education: MD, Tel Aviv University. Oncology residency, Tel Aviv Sourasky Medical Center. Advanced training in GI oncology, UCSF. Accreditations: Board certified in Oncology and Gastroenterology. Member, Israel Society of Oncology and Radiotherapy.
Israel offers proprietary immunology treatments including mitochondrial enrichment therapy and specialized CAR-T protocols for multiple myeloma. Leading centers like Hadassah Medical Center and Sheba Medical Center pioneer these cellular therapies. Patients access experimental stem cell treatments and advanced immunotherapy compatibility testing not widely available elsewhere.
Bookimed Expert Insight: Data shows that Israel's top hospitals, like Sourasky and Sheba, serve over 1,500,000 patients annually each. This massive volume allows them to run concurrent clinical trials for therapies like CAR-T years before they reach other markets. For patients with refractory conditions, these high-volume research hubs offer access to phase 3 trials that are often unavailable in the US or Europe.
Patient Consensus: Patients note that experimental treatments like mesenchymal stem cell infusions often work when standard biologics fail. They emphasize verifying clinical trial eligibility through official databases before making travel arrangements due to the specialized nature of these protocols.
Candidacy for immunotherapy in Israel depends on biomarker testing and clinical evaluation by specialists. Doctors at centers like Sourasky Medical Center (Ichilov) and Hadassah Medical Center analyze PD-L1 expression and tumor mutational burden. Your physical fitness (ECOG score) and treatment history also determine eligibility.
Bookimed Expert Insight: Data from major Israeli centers shows that volume directly impacts diagnostic speed. Sourasky Medical Center treats 400,000+ patients annually and uses in-house AI for faster biomarker analysis. Large facilities often provide results in days, which is vital for starting intensive treatment plans quickly.
Patient Consensus: Patients emphasize the importance of providing a complete autoimmune history early. They note that physical fitness often matters more than age when getting approved for these programs.
Immunotherapy is generally considered less toxic than chemotherapy because it specifically targets cancer cells while sparing healthy ones. It avoids systemic issues like hair loss and severe nausea. However, it carries unique risks of autoimmune inflammation in organs like the thyroid, lungs, or liver.
Bookimed Expert Insight: Israeli centers like Sourasky Medical Center report a 90% average success rate for oncology treatments, largely due to precise molecular diagnostics. Our data shows that top specialists, like Dr. Michael Lotem at Hadassah, focus on SLAM receptor research to predict immune responses. This advanced screening helps doctors identify patients at risk for rare complications before treatment even begins.
Patient Consensus: Many patients describe chemotherapy as a total body shutdown, while immunotherapy feels manageable and allows a faster return to work. They note it is important to track daily symptoms, as immune-related issues can appear months after starting.
Israeli immunology clinics treat various non-cancerous conditions. These include autoimmune disorders like lupus and rheumatoid arthritis. Specialists also manage severe allergies, primary immunodeficiencies, and neurological conditions like multiple sclerosis. Facilities in Tel Aviv and Jerusalem provide advanced diagnostics and specialized therapies for complex immune dysfunctions.
Bookimed Expert Insight: Israeli immunology centers often integrate research directly into clinical practice. Hadassah Medical Center and Sourasky Medical Center (Ichilov) frequently participate in international clinical trials. This allows patients access to newer biologics and monoclonal antibodies before they reach general global markets. Our data shows these clinics manage over 1,000,000 patients annually with 2,000+ specialized doctors.
Patient Consensus: Patients note that Israeli doctors often prescribe advanced biologics earlier than clinics in other countries. They appreciate the detailed baseline immune panels and the availability of intensive treatments like intravenous immunoglobulin (IVIG) therapy.
International patients can participate in clinical trials in Israel for immunology and autoimmune conditions. Major research centers like Hadassah Medical Center and Sheba Medical Center host numerous studies. Trials typically cover treatment costs and offer access to innovative therapies under strict Helsinki Committee ethical oversight.
Bookimed Expert Insight: Israeli medical centers demonstrate a high concentration of research expertise within single facilities. For example, Sourasky Medical Center employs 2,200 doctors across 240 departments. This density allows for faster internal referrals between immunologists and specialists in related fields. Patients at these high-volume hubs often benefit from more efficient screening processes for complex multi-system clinical trials.
Patient Consensus: Patients find that starting the process with a video call helps bridge the distance. They note that while clinical care is excellent, arranging the required medical visa can take up to 6 weeks.
No mandatory vaccinations are required to enter Israel for medical treatment. However, health officials strongly recommend updating routine immunizations like Measles (MMR), Polio, and Tetanus (Tdap) before arrival. These precautions protect patients in clinical settings where exposure risk is higher.
Bookimed Expert Insight: Data from major centers like Sourasky Medical Center and Hadassah shows they prioritize pre-treatment bloodwork over general travel shots. For immunology patients, doctors like Dr. Shmuel Kivity often focus on specific vaccine clearance for immunosuppressive therapies. Always share your full immunization record with your specialist during the initial consultation to avoid treatment delays.
Patient Consensus: Patients note that while no special shots are forced at the border, staying current on flu and COVID boosters is practical. They emphasize arriving early for appointments to manage stress, as hospital protocols focus heavily on screening rather than vaccination status.
Immunotherapy sessions in Israel typically involve a 30 to 90-minute intravenous infusion or a brief 15-minute injection. Patients receive treatment in specialized outpatient centers like Sourasky Medical Center (Ichilov). Procedures require prior blood tests to monitor liver and kidney function for patient safety.
Bookimed Expert Insight: Data shows that major Israeli hubs like Hadassah and Sheba Medical Center manage over 1,000,000 patients annually. This high volume allows these institutions to offer advanced clinical trials and SLAM receptor research. Patients visiting these centers often benefit from multidisciplinary teams led by specialists with 20+ years of experience.
Patient Consensus: Patients note the injection feels like a tiny pinch but recommend wearing loose sleeves for comfort. Many advise booking sessions months in advance due to high demand at public clinics.
Israel is a global leader in clinical immunology. Leading centers like Tel Aviv Sourasky Medical Center (Ichilov) and Sheba Medical Center are JCI-accredited. They specialize in treating complex immune disorders, primary immunodeficiencies, and HIV. These facilities integrate advanced molecular analysis with multidisciplinary clinical care.
Bookimed Expert Insight: Israeli hospitals often operate as primary referral centers for specific niches. For instance, Sourasky serves as the national hub for occupational asthma. Patients seeking second opinions should look for doctors with 20+ years of experience, like Dr. Evhenii Katsman, who handle complex overlaps between immunology and infectious diseases.
Patient Consensus: Patients note it's important to prepare for high-cost diagnostics. They often praise the quick access to specialists and emphasize that staff at major Jerusalem facilities speak excellent English.
Israeli immunology breakthroughs include CAR-T therapy for Alzheimer's and AI-driven immune system mapping. Researchers have developed the first bacterial mRNA vaccine and nanoparticle-based delivery systems. Centers like Hadassah Medical Center and Sheba Medical Center lead these global clinical trials for neurodegenerative and autoimmune diseases.
Bookimed Expert Insight: Data shows a clear trend toward decentralizing immunology care through oral and mucosal delivery. While most global therapies require clinical infusions, Israeli innovations at Sheba Medical Center focus on oral COVID/flu combo vaccines. This shift simplifies logistics for international patients traveling for long-term immune modulation.
Patient Consensus: Patients note that while breakthrough treatments are exciting, many remain in early trial phases. They suggest checking clinical trial registries and confirming specific drug side effects before starting new immunotherapy protocols.
Israel offers advanced clinical trials for immunology, autoimmune diseases, and rare genetic immunodeficiencies. Major centers like Sheba Medical Center and Sourasky Medical Center (Ichilov) conduct Phase II and III trials. These programs often feature CAR-T therapies, gene therapy pilots, and checkpoint inhibitors under strict Ministry of Health oversight.
Bookimed Expert Insight: Israeli hospitals often adopt cutting-edge immunology treatments faster than many European facilities. Data shows centers like Sourasky Medical Center and Hadassah Medical Center serve 1,000,000+ patients annually. This high volume allows these institutions to maintain diverse trial registries. Patients with rare or refractory conditions often find more active recruitment opportunities in Tel Aviv and Jerusalem.
Patient Consensus: Patients note that while administrative processes can be slow, the medical care is exceptional. They emphasize that having a rare condition may actually speed up the trial acceptance process.